It was purely a “business decision” and not indicative of the product’s efficacy, said Vericel Corp.’s new CEO Nick Colangelo to a room full of people at the first RegenMed Investor Day in New York on April 17. Colangelo’s comments referred to the company’s decision to call off a late-stage trial of Aastrom’s stem cell therapy in critical limb ischemia and shift its focus to dilated cardiomyopathy.
The decision to do so was announced March 27, less than a month after the company brought in new leadership...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?